Pipeline

Through joint collaborations with top pharmaceutical companies and research institutions, KREX has been used to identify autoantibody biomarkers for commercial diagnostics and screening applications. In addition, KREX has also been used to identify biologics with therapeutics potential.

Stage

Project

Pilot

Candidate id

Validation

Clinical Trial

Commercialisation

Companion Diagnostics

Cancer Immunotherapy PD1 inhibitor

Autoimmune Disease Drug 1

Autoimmune Disease Drug 2

Disease Diagnostics

Melanoma

NSCLC

Gastric Cancer

Breast Cancer

Therapeutic Autoantibodies

Rheumatoid Arthritis – A

Autism

Lupus

Parkinson’s

Aging

Rheumatoid Arthritis – B

FEATURED PRODUCTS

IMMUNOME
Protein Array

High-throughput
sero-profiling platform

CTA
Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Custom
Protein Array

Flexible format for
high-throughput screening

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

2008 – 2019 © Sengenics All rights reserved 

X